Axsome Therapeutics Q4 Revenue Jumps 65% to $196M, EPS at -$0.71
Axsome posted Q4 revenue of $196M, up 65% year-over-year, topping estimates, and delivered EPS of -$0.71 versus -$0.70 expected. Auvelity generated $155.1M in sales, Sunosi $36.7M and SYMBRAVO $4.1M, while full-year revenue grew 66% to $638.5M.
1. Q4 Financial Results
Axsome reported Q4 revenue of $196 million, a 65% increase year-over-year, and posted EPS of -$0.71 per share, missing projections by $0.01.
2. Q4 Product Sales Breakdown
Sales of Auvelity reached $155.1 million, representing approximately 80% of product net revenue, while Sunosi contributed $36.7 million and SYMBRAVO generated $4.1 million.
3. Full-Year 2025 Performance
For full-year 2025, Axsome achieved revenue of $638.5 million, up 66% compared to 2024, driven by the commercial strength of its central nervous system therapy portfolio.
Related News
VBCF
Vanguard’s BondBuilder ETFs Garner $242M, Join $70B Target Maturity Market
VBCF•
GS
Oil Prices Rebound to $99–$106 After Trump Iran Deal Comments, Inventories Drop
GS•
GROW
US Global Investors Sees 15% AUM Gain, 31% Revenue Growth and $2.6M Profit
GROW•
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
VBCH
Vanguard’s BondBuilder Suite Amasses $242M in Two Months, Fuels $70B ETF Segment
VBCH•
Sources
FFFFF
+1 more